In the following interview, the ASCO Daily News spoke with Stephen Leong, MD, of the University of Colorado School of Medicine, about immunotherapy’s progress in the field of gastrointestinal (GI) cancers and what he learned from abstracts presented during the 2018 ASCO Annual Meeting.
A high dose of a proton-pump inhibitor (PPI) combined with low-dose aspirin reduced the risk of death, esophageal adenocarcinoma (EA), or high-grade dysplasia (HGD) in patients with Barrett’s esophagus (BE) in a long-term, phase III randomized trial.
The combination of temozolomide and capecitabine resulted in improved progression-free and overall survival (Abstract 4004) compared with temozolomide monotherapy in patients with advanced pancreatic neuroendocrine tumors (NETs).
Neoadjuvant chemoradiotherapy resulted in improved outcomes compared with immediate surgery in patients with resectable and borderline resectable pancreatic cancer, according to results of the phase III PREOPANC trial (Abstract LBA4002).
Adjuvant chemotherapy with a modified FOLFIRINOX (mFOLFIRINOX) regimen was superior to gemcitabine with regard to disease-free, metastasis-free, and overall survival (OS) in patients with resected pancreatic cancer, according to a new randomized phase III trial.
The addition of oxaliplatin hyperthermic peritoneal chemotherapy (HIPEC) combined with cytoreductive surgery in patients with colorectal peritoneal carcinomatosis does not improve overall survival (OS) or recurrence-free survival (RFS).
Gallbladder cancer (GBC) is rare in Europe, the United States, and Canada. However, in some areas of South America, particularly in the Andean region of Chile, Ecuador, Peru, and Bolivia, the incidence and mortality rate are high.
The Extended Education Session “Management of Complex Upper Gastrointestinal Cases: Implementation of Best Evidence,” to be held on June 2, will address these and other questions facing oncologists specializing in upper GI cancers.
The guideline, organized into 21 recommendations of how to use molecular biomarkers to diagnose and treat patients with colorectal cancer, represented an unprecedented collaboration between four organizations: CAP, ASCP, the Association for Molecular Pathology, and ASCO.
Patients with potentially curable pancreatic cancer should be treated with two medications—gemcitabine and capecitabine—after tumor resection, as long as there are no concerns about toxicity and chemotherapy.
Phase III trial CALGB 80802 failed to demonstrate OS benefit with addition of doxorubicin to sorafenib in the first-line treatment of advanced HCC. The results contradict earlier phase II data, and suggest that the role of chemotherapy in advanced HCC could come to an end.
The benefits of palliative care for patients with advanced cancer and short life expectancy has been well established. New research suggests this care could improve quality of life and mood both among patients with lung and GI cancers early in the course of disease and their caregivers.
This Education Session offers insight into how past failures in gastric cancer, along with emerging genetic and molecular information, hold good solutions to solving the current treatment conundrum for this disease.